114 related articles for article (PubMed ID: 15576362)
1. Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia.
Kypreos KE; van Dijk KW; Havekes LM; Zannis VI
J Biol Chem; 2005 Feb; 280(8):6276-84. PubMed ID: 15576362
[TBL] [Abstract][Full Text] [Related]
2. Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.
Gorshkova IN; Kypreos KE; Gantz DL; Zannis VI; Atkinson D
Biochemistry; 2008 Nov; 47(47):12644-54. PubMed ID: 18959431
[TBL] [Abstract][Full Text] [Related]
3. Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein.
Drosatos K; Kypreos KE; Zannis VI
Biochemistry; 2007 Aug; 46(33):9645-53. PubMed ID: 17655277
[TBL] [Abstract][Full Text] [Related]
4. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice.
Kypreos KE; Morani P; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2001 May; 40(20):6027-35. PubMed ID: 11352738
[TBL] [Abstract][Full Text] [Related]
5. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.
Chroni A; Kan HY; Kypreos KE; Gorshkova IN; Shkodrani A; Zannis VI
Biochemistry; 2004 Aug; 43(32):10442-57. PubMed ID: 15301543
[TBL] [Abstract][Full Text] [Related]
6. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion.
Kypreos KE; van Dijk KW; van Der Zee A; Havekes LM; Zannis VI
J Biol Chem; 2001 Jun; 276(23):19778-86. PubMed ID: 11279066
[TBL] [Abstract][Full Text] [Related]
7. apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.
Fotakis P; Vezeridis A; Dafnis I; Chroni A; Kardassis D; Zannis VI
J Lipid Res; 2014 Jul; 55(7):1310-23. PubMed ID: 24776540
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological properties.
Lampropoulou A; Zannis VI; Kypreos KE
Biochem Pharmacol; 2012 Dec; 84(11):1451-8. PubMed ID: 22985620
[TBL] [Abstract][Full Text] [Related]
9. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT.
Kypreos KE; Zannis VI
Biochem J; 2007 Apr; 403(2):359-67. PubMed ID: 17206937
[TBL] [Abstract][Full Text] [Related]
10. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
Kypreos KE
Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
[TBL] [Abstract][Full Text] [Related]
11. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice.
Kypreos KE; Zannis VI
J Lipid Res; 2006 Mar; 47(3):521-9. PubMed ID: 16339113
[TBL] [Abstract][Full Text] [Related]
12. The aminoterminal 1-185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I deficient mice.
Petropoulou PA; Gantz DL; Wang Y; Rensen PC; Kypreos KE
Atherosclerosis; 2011 Nov; 219(1):116-23. PubMed ID: 21802082
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
de Beer F; van Dijk KW; Jong MC; van Vark LC; van der Zee A; Hofker MH; Fallaux FJ; Hoeben RC; Smelt AH; Havekes LM
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain.
Gerritsen G; Kypreos KE; van der Zee A; Teusink B; Zannis VI; Havekes LM; van Dijk KW
J Lipid Res; 2003 Feb; 44(2):408-14. PubMed ID: 12576523
[TBL] [Abstract][Full Text] [Related]
15. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice.
Tsukamoto K; Maugeais C; Glick JM; Rader DJ
J Lipid Res; 2000 Feb; 41(2):253-9. PubMed ID: 10681409
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
[TBL] [Abstract][Full Text] [Related]
17. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins.
Dong LM; Weisgraber KH
J Biol Chem; 1996 Aug; 271(32):19053-7. PubMed ID: 8702576
[TBL] [Abstract][Full Text] [Related]
18. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.
Zannis VI; Chroni A; Kypreos KE; Kan HY; Cesar TB; Zanni EE; Kardassis D
Curr Opin Lipidol; 2004 Apr; 15(2):151-66. PubMed ID: 15017358
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.
Mensenkamp AR; Jong MC; van Goor H; van Luyn MJ; Bloks V; Havinga R; Voshol PJ; Hofker MH; van Dijk KW; Havekes LM; Kuipers F
J Biol Chem; 1999 Dec; 274(50):35711-8. PubMed ID: 10585451
[TBL] [Abstract][Full Text] [Related]
20. Lipoproteins produced by ApoE-/- astrocytes infected with adenovirus expressing human ApoE.
Peng D; Song C; Reardon CA; Liao S; Getz GS
J Neurochem; 2003 Sep; 86(6):1391-402. PubMed ID: 12950448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
